Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| STUDY00021446 | Other Identifier | Fred Hutch/University of Washington Cancer Consortium | |
| NCI-2024-10011 | Registry Identifier | CTRP (Clinical Trial Reporting Program) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This phase I/II trial examines if buffered lidocaine reduces the pain that patients may experience during prostate biopsy. Prostate biopsies are typically performed awake, in the office, with only local anesthetic. As a result, many patients note considerable pain during these procedures. Local anesthetics such as lidocaine are typically acidic, which is thought to cause pain and burning during infiltration (injection). As a result, buffered local anesthetic has become the standard of care (SOC) in multiple specialties using awake local anesthetic. However, it has not been explored during prostate biopsies. Adminstering buffered lidocaine may reduce pain in patients undergoing prostate biopsy.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive SOC lidocaine via injection during SOC prostate biopsy on study.
ARM B: Patients receive buffered lidocaine via injection during SOC prostate biopsy on study.
After completion of study intervention, patients are followed up 1-2 days post-biopsy.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm A (lidocaine) | Active Comparator | Patients receive SOC lidocaine via injection during SOC prostate biopsy on study. |
|
| Arm B (buffered lidocaine) | Experimental | Patients receive buffered lidocaine via injection during SOC prostate biopsy on study. (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio) | Drug | Given via injection |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pain of Local Anesthetic Injection | Pain associated with the injection of local anesthetic, assessed by a written questionnaire (Visual Analogue Scale, 0 [least] to 10 [worst pain]). | Within 20 seconds of completing the injection of all local anesthetic |
| Measure | Description | Time Frame |
|---|---|---|
| Pain of the Prostate Biopsy | Pain associated with the biopsies of the prostate, assessed by a questionnaire (Visual Analogue Scale, 0 [least] to 10 [worst pain]). | Within 10 minutes of completing the prostate biopsy, and on post-operative day 1 |
| Willingness to perform another prostate biopsy in the future, if medically necessary |
Not provided
Inclusion Criteria:
Provision of signed and dated informed consent form
18 years old or older
Patients with prostates
Those with and without a prior diagnosis of prostate cancer
Recommended to undergo a prostate biopsy in the urology clinic. Only patients that have been scheduled for a biopsy (for clinical purposes) will be enrolled. May include all of the following types of prostate biopsies:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alexander Zhu, DO | Fred Hutch/University of Washington Cancer Consortium | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98195 | United States |
This is a single center, investigator initiated trial.
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| ICF | No | No | Yes | Informed Consent Form | Dec 6, 2024 | Feb 11, 2026 |
Not provided
Not provided
Not provided
Not provided
The Investigational Drug Services team will be unblinded to the patient's randomization status. During statistical analysis of the data, the statistician will be concealed to the randomization allocation.
| Lidocaine | Drug | Given via injection |
|
| Biopsy of Prostate | Procedure | Undergo SOC prostate biopsy |
|
|
| Questionnaire Administration | Other | Ancillary studies |
|
Assessed by a questionnaire (Visual Analogue Scale, 0 [least likely] to 10 [most likely]) |
| Within 10 minutes of completing the prostate biopsy, and on post-operative day 1 |
| Incidence of adverse events | Will be assessed by patient self-report using an electronic written questionnaire. Will be assessed for inability to urinate, bleeding, allergic reaction, fever, or fatigue, or significant chills, or nausea/vomiting. | Post-operative day 1 |
| ICF_000.pdf |
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D008012 | Lidocaine |
| D017693 | Sodium Bicarbonate |
| ID | Term |
|---|---|
| D000083 | Acetanilides |
| D000813 | Anilides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000814 | Aniline Compounds |
| D000588 | Amines |
| D001639 | Bicarbonates |
| D002254 | Carbonates |
| D002255 | Carbonic Acid |
| D017554 | Carbon Compounds, Inorganic |
| D007287 | Inorganic Chemicals |
| D017670 | Sodium Compounds |
Not provided
Not provided